While the role of B cells in tumour immunity remains complex, our findings suggest that IL17A depletion may shift the immune environment to favour B‐cell activation and antibody production, possibly through reduced immunosuppressive cytokine signalling or altered antigen presentation within the tumour stroma. This evidence concerns the gene IL17A and neoplasm.